| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
ErythropoietinNeuroprotective agentsStroke (BASKET)Anemia (Renal)Myelodysplastic syndromeAutoantibodies Anti ErythropoieteinSepsisHIF1alpha und HIF1 (BASKET)Kindey (REPOS cells)| 1 | 2008 | Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. | 
| + | - | nl | J Intern Med 264(5):405-32 (2008) |
| 2 | 2002 | Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. |
| + | - | nl | J Cereb Blood Flow Metab 22(5):503-14 (2002) |
| 3 | 2010 | A systematic review and meta-analysis of erythropoietin in experimental stroke. |
| + | - | nl | J Cereb Blood Flow Metab 30(5):961-8 (2010) |
| 4 | 2007 | Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin Receptor Activator). |
| + | - | nl | Int J Nanomedicine 2(1):33-8 (2007) |
| 5 | 2009 | Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). |
| + | - | nl | Clin J Am Soc Nephrol 4(2):470-80 (2009) |
| 6 | 1991 | Analysis of physician questions in an ambulatory care setting. |
| + | - | nl | Proc Annu Symp Comput Appl Med Care -(-):995-9 (1991) |
| 7 | 2007 | Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. |
| + | - | nl | Clin J Am Soc Nephrol 2(6):1274-82 (2007) |
| 8 | 2008 | Erythropoietins in cancer patients: ESMO recommendations for use. |
| + | - | nl | Ann Oncol 19 Suppl 2(-):ii113-5 (2008) |
| 9 | 2007 | Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. |
| + | - | nl | Cancer 110(3):477-88 (2007) |
| 10 | 2006 | Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review. |
| + | - | nl | Cancer 106(1):223-33 (2006) |
| 11 | 2005 | Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. |
| + | - | nl | J Natl Cancer Inst 97(7):489-98 (2005) |
| 12 | 2009 | Is nephrology more at ease than oncology with erythropoiesis-stimulating agents? Treatment guidelines and an update on benefits and risks. |
| + | - | nl | Oncologist 14 Suppl 1(-):57-62 (2009) |
| 13 | 2009 | Anemia management in oncology and hematology. |
| + | - | nl | Oncologist 14 Suppl 1(-):43-56 (2009) |
| 14 | 2009 | Examining the involvement of erythropoiesis-stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic events. |
| + | - | nl | Oncologist 14 Suppl 1(-):34-42 (2009) |
| 15 | 2009 | Update on anemia management in nephrology, including current guidelines on the use of erythropoiesis-stimulating agents and implications of the introduction of "biosimilars". |
| + | - | nl | Oncologist 14 Suppl 1(-):16-21 (2009) |
| 16 | 2009 | Update on erythropoiesis-stimulating agents and clinical trials in oncology. |
| + | - | nl | Oncologist 14 Suppl 1(-):6-15 (2009) |
| 17 | 2009 | An update on twenty years of anemia management with erythropoiesis-stimulating agents in nephrology and oncology/hematology. |
| + | - | nl | Oncologist 14 Suppl 1(-):1-5 (2009) |
| 18 | 2008 | The role of recombinant erythropoietin in childhood cancer. |
| + | - | nl | Oncologist 13(2):157-66 (2008) |
| 19 | 2008 | Venous thromboembolic events and erythropoiesis-stimulating agents: an update. |
| + | - | nl | Oncologist 13 Suppl 3(-):11-5 (2008) |
| 20 | 2008 | Safety update on erythropoiesis-stimulating agents: trials within and outside the accepted indications. |
| + | - | nl | Oncologist 13 Suppl 3(-):4-10 (2008) |
| 21 | 2008 | Editorial: anemia management with erythropoiesis-stimulating agents: a risk-benefit update. |
| + | - | nl | Oncologist 13 Suppl 3(-):1-3 (2008) |
| 22 | 2007 | Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. |
| + | - | nl | Oncologist 12(10):1264-73 (2007) |
| 23 | 2004 | Apoptotic mechanisms in the control of erythropoiesis. |
| + | - | nl | Leukemia 18(7):1176-99 (2004) |
| 24 | 2003 | Erythropoietin: physiology and pharmacology update. |
| + | - | nl | Exp Biol Med (Maywood) 228(1):1-14 (2003) |
| 25 | 2002 | EPO's alter ego: erythropoietin has multiple actions. |
| + | - | nl | Stem Cells 20(6):485-92 (2002) |
| 26 | 1993 | Signal transduction in the erythropoietin receptor system. |
| + | - | nl | Stem Cells 11(5):381-92 (1993) |
| 27 | 2008 | Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. |
| + | - | nl | Blood 111(1):25-41 (2008) |
| 28 | 1991 | Erythropoietin. |
| + | - | nl | Blood 77(3):419-34 (1991) |
| 29 | 2008 | Pure red cell aplasia induced by erythropoiesis-stimulating agents. |
| + | - | nl | Clin J Am Soc Nephrol 3(1):193-9 (2008) |
| 30 | 2008 | Novel erythropoiesis-stimulating agents: a new era in anemia management. |
| + | - | nl | Clin J Am Soc Nephrol 3(1):200-7 (2008) |
| 31 | 1998 | Biology of erythropoietin. |
| + | - | nl | Haematologica 83(8):724-32 (1998) |
| 32 | 2001 | Erythropoietin: a paradigm for the development of practice guidelines. |
| + | - | nl | Hematology Am Soc Hematol Educ Program -(-):10-30 (2001) |
| 33 | 2004 | Molecular biology of erythropoietin. |
| + | - | nl | Intern Med 43(8):649-59 (2004) |
| 34 | 2003 | Pleiotropic functions of erythropoietin. |
| + | - | nl | Intern Med 42(2):142-9 (2003) |
| 35 | 2006 | Erythropoietin in clinical practice: current use, effect on survival, and future directions. |
| + | - | nl | Isr Med Assoc J 8(10):703-6 (2006) |
| 36 | 2002 | Erythropoietin and its receptor: signaling and clinical manifestations. |
| + | - | nl | Isr Med Assoc J 4(11):1072-6 (2002) |
| 37 | 2008 | Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. |
| + | - | nl | JAMA 299(8):914-24 (2008) |
| 38 | 2007 | Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies. |
| + | - | nl | Mayo Clin Proc 82(11):1371-80 (2007) Wish JB |
| 39 | 2007 | Recombinant EPO production--points the nephrologist should know. |
| + | - | nl | Nephrol Dial Transplant 22(10):2749-53 (2007) |
| 40 | 1999 | The molecular biology of erythropoietin. |
| + | - | nl | Nephrol Dial Transplant 14 Suppl 2(-):22-8 (1999) |
| 41 | 2003 | Recombinant erythropoietin in clinical practice. |
| + | - | nl | Postgrad Med J 79(933):367-76 (2003) |
| 42 | 1991 | The use of erythropoietin in renal failure. |
| + | - | nl | Postgrad Med J 67(783):9-15 (1991) |
| 43 | 1992 | Erythropoietin therapy in patients with chronic renal failure. |
| + | - | nl | West J Med 157(2):154-7 (1992) |
| 44 | 2009 | Use of agents stimulating erythropoiesis in digestive diseases. |
| + | - | nl | World J Gastroenterol 15(37):4675-85 (2009) |
| 45 | 1997 | Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. |
| + | - | nl | Kidney Int 51(3):622-30 (1997) |
| 46 | 1996 | Erythropoietin in chronic renal failure. |
| + | - | nl | Kidney Int 50(4):1373-91 (1996) |
| 47 | 1993 | Molecular biology of erythropoietin. |
| + | - | nl | Kidney Int 44(4):887-904 (1993) |
| 48 | 1989 | The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. |
| + | - | nl | Kidney Int 35(1):134-48 (1989) |
| 49 | 2009 | Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. |
| + | - | nl | CMAJ 180(11):E62-71 (2009) |
| 50 | 2007 | Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials. |
| + | - | nl | CMAJ 177(7):725-34 (2007) Zarychanski R |
| 51 | 2004 | Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here? |
| + | - | nl | Nephrol Dial Transplant 19(2):288-93 (2004) |
| 52 | 2010 | Nonhematopoietic variants of erythropoietin in ischemic stroke: need for step-wise proof-of-concept studies. |
| + | - | nl | ScientificWorldJournal 10(-):2285-7 (2010) |
| 53 | 2010 | Non-erythroid effects of erythropoietin. |
| + | - | nl | Haematologica 95(11):1803-5 (2010) Arcasoy MO |
| 54 | 2003 | New insights into erythropoietin and epoetin alfa: mechanisms of action, target tissues, and clinical applications. |
| + | - | nl | Oncologist 8 Suppl 3(-):18-29 (2003) |
| 55 | 2010 | Bench to bedside: A role for erythropoietin in sepsis. |
| + | - | nl | Crit Care 14(4):227 (2010) |
| 56 | 2010 | Hypoxic regulation of erythropoiesis and iron metabolism. | 
| + | - | nl | Am J Physiol Renal Physiol 299(1):F1-13 (2010) |
| 57 | 2010 | Regulated oxygen sensing by protein hydroxylation in renal erythropoietin-producing cells. |
| + | - | nl | Am J Physiol Renal Physiol 298(6):F1287-96 (2010) |
